Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Brindley Sonal Hapuarachi"'
Autor:
Clare Hodgson, Andrew J Wallace, Robert Metcalf, Guy N J Betts, Brindley Sonal Hapuarachi, Laura Feeney, Tracy Hussell, Kevin J. Harrington, Helen Adderley, Samuel Rack, David H. J. Morgan
Publikováno v:
Adderley, H, Rack, S, Hapuarachi, B, Feeney, L, Morgan, D, Hussell, T, Wallace, A J, Betts, G, Hodgson, C, Harrington, K & Metcalf, R 2021, ' The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma ', Oral Oncology, vol. 113, 105095 . https://doi.org/10.1016/j.oraloncology.2020.105095
OBJECTIVES: Despite wide excision and post-operative irradiation, loco-regional and/or metastatic recurrence is a significant clinical problem in salivary adenoid cystic carcinoma (SACC). Reliable biomarkers are required to tailor post-treatment surv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e49bbf83042417c7b0f26bc7f9a50e8
https://pubmed.ncbi.nlm.nih.gov/33290961
https://pubmed.ncbi.nlm.nih.gov/33290961
Autor:
Helen Adderley, Rami Rauch, Laura Feeney, Kevin J. Harrington, Robert Metcalf, Elad Herz, Guy N J Betts, Brindley Sonal Hapuarachi, David H. J. Morgan, Russell W. Walker, Sam Rack
Publikováno v:
Journal of Clinical Oncology. 39:6072-6072
6072 Background: ACC is a rare salivary cancer for which effective drug therapies remain lacking. The highest rates of disease recurrence are in patients with NOTCH pathway activation, which is reported in 10-20% of ACC tumors. Novel drugs targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b0cc3a9132626f9d279b434dcd3b55f
https://doi.org/10.1200/jco.2021.39.15_suppl.6072
https://doi.org/10.1200/jco.2021.39.15_suppl.6072
Autor:
Laura Woodhouse, Valentinos Kounnis, Konstantinos Kamposioras, Jamie M J Weaver, Brindley Sonal Hapuarachi, Neethu Billy Graham Mariam, Wasat Mansoor, Rebecca Lee, Richard A Hubner, Fiona Britton, Thomas K. Waddell, Adeel M Khan, Kathleen Connors, Jessica Coyle
Publikováno v:
Journal of Clinical Oncology. 39:4039-4039
4039 Background: Despite potentially curative surgery, long-term survival from OGC remains poor due to high relapse rate. Neoadjuvant (naFLOT) and adjuvant (aFLOT) FLOT is currently standard treatment for resectable OGC based on data from the FLOT-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::539c7d0ef6f47d6ac2bd9884eb5a438b
https://doi.org/10.1200/jco.2021.39.15_suppl.4039
https://doi.org/10.1200/jco.2021.39.15_suppl.4039